We are 100% patient-focused. LUNGevity Foundation funds research that has potential to revolutionize outcomes for those diagnosed with lung cancer. With our strategic approach in two priority areas—finding lung cancer early and treating it more effectively—our research speeds breakthroughs to patients so people can live longer and better lives.
The LUNGevity Scientific Advisory Board meets annually to discuss research strategy and share new scientific developments. In addition, LUNGevity convenes a formal study section with Scientific Advisory Board members and other lung cancer experts who identify, among the grant applications we receive, the most promising proposals for research into the early detection and treatment of lung cancer. Awardees are encouraged to, and frequently do, form promising collaborations with these lung cancer experts.
The lung cancer experts who review the grant applications assess them on a number of measures, including the likelihood that the proposed research will exert a sustained, powerful influence on the research field involved.
What We Fund
We are particularly interested in:
- Finding effective biomarkers that can be used to develop a non-invasive strategy for detecting early-stage lung cancer
- Developing more specific lung cancer imaging techniques by improving current software, hardware, data-sharing methods, and testing protocols
- Creating more effective and efficient therapies to treat lung cancer at all stages of the disease and helping to bring these therapies to patients quickly
While we have particular interests, they do not bind us. LUNGevity welcomes innovative and novel approaches that can lead to the development of early detection and treatment practices of lung cancer.